Dr Maria Esposito awarded the John Goldman Fellowship to investigate chemotherapy resistance
- Tuesday, May 8, 2018
The £118,000 fellowship will involve working with leukaemia patents in collaboration with Barts Cancer Institute.
Dr Maria Teresa Esposito, of the University of Roehampton's Department of Life Sciences, has been granted the prestigious John Goldman Fellowship for Future Science to research chemotherapy resistance in leukaemia patients. The £118,000 fellowship will involve working with leukaemia patients in collaboration with Barts Cancer Institute.
It provides funding for two years to conduct a research project alongside Barts Cancer Institute, which will be providing tissue samples. There will be postdoctoral researcher to assist with the project, which will focus on Mixed Lineage Leukaemia, a particularly aggressive form of the disease for which there is no effective therapeutic approach. Dr Esposito's work will follow and expand upon her previous research into cancer treatments.
The John Goldman Fellowship is awarded by Leuka, a leukaemia treatment research charity. The Fellowships are given to ‘those with a passion for science, and a desire to develop new ideas and translate scientific advances into clinical practice’. They are named for John Goldman, a founder of Leuka and renowned haematologist and clinician in the field of leukaemia treatment.
Dr Esposito said, ‘It's an honour to receive this Fellowship from Leuka. I hope that my research will allow us not only to increase our knowledge on the biology of leukaemia but also to help us to design new therapies and spare families from the suffering of living with this disease’.
In addition to the reward itself, Roehampton has match-funded the amount granted in the fellowship. Find out more about the John Goldman Fellowship on Leuka's website. Find out more about the work of Barts Cancer Institute here.